Datroway (datopotamab deruxtecan) TNBC coverage guide: the first TROP2 ADC for first-line triple-negative breast cancer — access, coding, PA criteria, and payer coverage

On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo / AstraZeneca) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes Datroway the first TROP2-directed antibody-drug conjugate (ADC) cleared for first-line metastatic TNBC — and the first medicine to demonstrate a statistically significant overall survival benefit in this setting compared to chemotherapy.

The approval is based on the phase 3 TROPION-Breast02 trial, which showed a 43% reduction in the risk of disease progression (HR 0.57) and a 21% reduction in the risk of death (HR 0.79) versus investigator's choice of chemotherapy. Datroway is the second TROP2 ADC to reach the US market after Trodelvy (sacituzumab govitecan), and the first approved in the first-line setting.

This guide is for oncology access teams, pharmacists, specialty pharmacy professionals, and payer strategists who need to understand Datroway's regulatory status, clinical evidence, HCPCS coding, formulary positioning, prior authorization requirements, and how it compares to Trodelvy.

Short answer

How Datroway works

Datroway is a TROP2-directed ADC built on Daiichi Sankyo's proprietary DXd ADC technology platform. It has three components:

1. Humanized anti-TROP2 IgG1 monoclonal antibody — targets TROP2 (trophoblast cell surface antigen 2), a protein broadly expressed on TNBC and other solid tumors
2. Tetrapeptide-based cleavable linker — stable in circulation but cleaved inside tumor cells
3. DXd payload (exatecan derivative) — a topoisomerase I inhibitor that causes DNA damage and apoptotic cell death

The cleavable linker enables a bystander effect: DXd payload released inside a TROP2-expressing tumor cell can diffuse to neighboring cancer cells, potentially overcoming heterogeneous TROP2 expression. No companion diagnostic is required — TROP2 expression testing is not needed for patient selection.

Datroway uses the same DXd ADC platform as Enhertu (trastuzumab deruxtecan), AstraZeneca and Daiichi Sankyo's flagship ADC.

Clinical evidence: TROPION-Breast02

The FDA approval was based on TROPION-Breast02 (NCT05374512), a global, multicenter, open-label, randomized phase 3 trial.

Design:

• 644 patients with previously untreated unresectable or metastatic TNBC who were not candidates for PD-1/PD-L1 inhibitor therapy
• 1:1 randomization: Datroway 6 mg/kg IV Q3W vs. investigator's choice of chemotherapy
• Chemotherapy arm: nab-paclitaxel (54%), paclitaxel (28%), eribulin (11%), carboplatin (4.7%), capecitabine (2.2%)
• Dual primary endpoints: PFS by blinded independent central review (BICR) and overall survival (OS)
• Stratified by geographic region, PD-L1 status, and disease-free interval

Efficacy results:

Dr. Tiffany A. Traina (MSKCC), a TROPION-Breast02 investigator, stated: "Datopotamab deruxtecan is the first and only medicine to significantly prolong overall survival in the 1st-line setting compared to chemotherapy in patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy."

The trial included patients with de novo or recurrent disease regardless of disease-free interval, and patients with stable brain metastases were eligible. Results were published in the Annals of Oncology (online April 3, 2026) and presented at the 2025 ESMO Congress.

Safety profile

Datroway has no boxed warning and no REMS program. The prescribing information includes warnings for:

In TROPION-Breast02, serious adverse reactions occurred in 17% of Datroway patients, with fatal adverse reactions in 0.3% (one ILD case). Permanent discontinuation was 4.7%, dose interruptions 35%, and dose reductions 28%. Median treatment duration was 8.5 months.

Datroway vs. Trodelvy: the TROP2 TNBC comparison

Two TROP2-directed ADCs now compete in TNBC. Understanding the differences is critical for formulary positioning and step therapy decisions.

Note: These trials cannot be directly compared due to different designs, control arms, and patient populations.

Trodelvy's ASCENT-03 trial in first-line TNBC showed positive PFS but immature OS data. Gilead has filed for the first-line indication in the US and Europe, with EMA's CHMP recommending approval. If approved, Trodelvy and Datroway would compete head-to-head in the first-line setting.

Some payers (e.g., GEHA) already list Trodelvy as "Preferred" and Datroway as "Non-preferred" for applicable indications, which would require step therapy through Trodelvy before Datroway. Access teams should audit plan-specific formulary positioning early.

HCPCS coding and billing

Billing units: 1 unit = 1 mg. For a typical 70 kg patient at 6 mg/kg (420 mg dose), that is 420 billable units per cycle.

Revenue code: CMS requires revenue code 0636 (drugs requiring detailed coding) for hospital outpatient claims for Medicare beneficiaries. Other payers may require pharmacy revenue codes from the 025X or 026X series.

NDC: 65597-801-01 (100 mg single-dose vial, 10-digit) or 65597-0801-01 (11-digit).

Datroway is administered under the medical benefit as a buy-and-bill drug. Providers purchase the drug, administer the infusion, and bill under the medical benefit using J9011. The drug is classified as a hazardous agent — appropriate handling procedures are required.

Payer coverage and prior authorization

NCCN added Datroway as a Category 1 Preferred first-line treatment option for metastatic TNBC patients not candidates for immunotherapy shortly after FDA approval. This classification strengthens prior authorization and appeal cases.

Typical prior authorization criteria require:

• Age ≥18 years
• ECOG performance status 0–1
• Confirmed TNBC diagnosis (ER-negative, PR-negative, HER2-negative by IHC/ISH)
• Not a candidate for PD-1/PD-L1 inhibitor therapy
• No prior systemic therapy for unresectable or metastatic disease
• No history of interstitial lung disease or pneumonitis requiring systemic steroids
• No clinically significant corneal disease
• Prescribed by or in consultation with an oncologist

Authorization periods typically run 6–12 months, renewable upon re-review for efficacy and tolerability. Arkansas Blue Cross, for example, grants initial and continuation approval for the treatment course or 12 months (whichever comes first). Some payers apply step therapy requirements (try Trodelvy first) or preferred/non-preferred tier positioning.

Patient assistance

The Datroway4U patient support program offers:

• Commercially insured patients: May pay as little as $0 per infusion through the savings program
• Infusion cost support: Up to $100 per administration for infusion-related costs
• Eye exam support: Up to $250 per eye exam (recommended every 3 cycles)
• First dose bridge: If there is a delay in a coverage decision, DATROWAY4U may provide the first dose at no cost
• Prior authorization assistance: Specialists complete benefit verification within 1 business day and provide PA requirements and required forms
• Sample letter of medical necessity and appeal templates available for download
• Uninsured patients: Contact Datroway4U for assistance options

Program enrollment is through the Datroway4U website or by calling 1-855-DATRO4U (1-855-328-7648). A completed enrollment form requires signatures from both physician and patient.

What this means for access teams

For manufacturer teams: Datroway enters the TNBC market with a first-mover advantage in first-line treatment — Trodelvy's first-line filing is still under review. The NCCN Category 1 Preferred status provides strong PA support. The key competitive question is whether payers will position Datroway ahead of Trodelvy (once Trodelvy's first-line indication is approved) based on the OS benefit and more convenient once-per-cycle dosing.

For payer teams: Datroway represents a meaningful clinical advance in first-line TNBC, but at a substantial cost. The WAC of ~$4,891 per 100 mg vial translates to approximately $20,000–$25,000 per cycle. With median treatment duration of 8.5 months, total drug cost per patient could reach $70,000–$215,000 at WAC before rebates. Payers should consider utilization management pathways, including confirmation of PD-1/PD-L1 ineligibility, and monitor the Trodelvy first-line filing for comparative positioning.

For oncology pharmacists and providers: Datroway requires premedication (preservative-free lubricant eye drops, steroid-containing mouthwash, diphenhydramine, acetaminophen, antiemetics) and monitoring for ILD, ocular toxicity, and stomatitis. The once-every-3-weeks schedule is more convenient than Trodelvy's twice-per-cycle schedule, which may favor administration at community oncology practices.

What to monitor next

• Trodelvy first-line TNBC filing: Gilead's ASCENT-03 data are under FDA review. A first-line approval would create direct formulary competition.
• Project Orbis international approvals: The Datroway TNBC application was reviewed under Project Orbis with concurrent reviews in Australia, Canada, Singapore, and Switzerland. Submissions are also underway in the EU, China, and Japan.
• Datroway NSCLC indication: Datroway already holds accelerated approval in previously treated EGFR-mutated NSCLC (June 2025). Confirmatory data are pending.
• Urothelial cancer pipeline: AstraZeneca and Daiichi Sankyo have more than 20 ongoing Datroway trials, including in urothelial cancer. Additional indications could expand the addressable market.
• Biosimilar and ADC market dynamics: Datroway's sales reached $218 million in 2025 and $102 million in Q1 2026. AstraZeneca has projected peak annual sales of up to $5 billion across all indications.
• PD-L1 testing and immunotherapy eligibility: The "not candidates for PD-1/PD-L1 inhibitor therapy" criterion requires clear clinical documentation. Access teams should establish standardized workflows for PD-L1 testing and documentation of ineligibility.

Sources

• FDA. "FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic Triple-Negative Breast Cancer." May 22, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer
• AstraZeneca. "Datroway Approved in US for 1L Triple-Negative Breast Cancer." Press release, May 22, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-us-for-1l-triple-negative-bc.html
• Dent R, et al. "Datopotamab deruxtecan versus chemotherapy in first-line metastatic triple-negative breast cancer." Annals of Oncology. Published online April 3, 2026.
• HCPCS Data. "J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg." https://www.hcpcsdata.com/Codes/J/J9011
• North Dakota Insurance Department. "Drug Transparency Filings 2025 — Daiichi Sankyo." https://www.insurance.nd.gov/sites/www/files/documents/Drug%20Transparency/Manufacturer/Filings/2025/Increase/Daiichi%20Sankyo%2C%20Inc.%20012825.csv
• CarelonRx. "DrugInsights Q1 2025." https://www.carelonrx.com/content/dam/digital/carelon/pdf/DrugInsights-Q125.pdf
• Datroway4U. "Coding and Reimbursement." https://www.datroway4u.com/hcp/coding-and-reimbursement
• Drugs.com. "Datroway Pricing." https://www.drugs.com/price-guide/datroway
• GEHA. "Coverage Policy: Datroway." https://www.geha.com/~/media93/Project/GEHA/GEHA/documents-files/coverage-policies/geha-coverage-policy-datroway.pdf
• Fierce Pharma. "AZ/Daiichi Datroway Outshines Gilead Trodelvy in First Global TROP2 Showdown." 2025. https://www.fiercepharma.com/pharma/az-daiichi-datroway-outshines-gilead-trodelvy-first-global-trop2-showdown